Compare Quantum Computing Inc (QUBT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs ResMed Inc. — how do they compare? Quantum Computing Inc trades at $8.03 (market cap $1.86B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 17.1× Quantum Computing Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| QUBT | RMD | |
|---|---|---|
Market Cap | $1.86B | $31.89B |
Sector | Technology | Health |
52-Week High | $24.62 | $283.28 |
52-Week Low | $6.31 | $182.82 |
Enterprise Value | $927.53M | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $8.22, up 2.62% today, amid bearish technical signals and challenging fundamentals. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, with negative profit margins across all metrics. However, analyst sentiment remains optimistic with a 75% buy rating and $19 consensus price target, supported by recent government funding announcements and institutional investments from BlackRock and Bank of New York Mellon.
QUBT offers speculative growth potential in quantum computing but carries significant execution risks. The stock's 131% upside to analyst targets contrasts with persistent losses and high cash burn. Investors face volatility from unproven technology commercialization while banking on long-term quantum adoption. Key catalysts include contract wins and manufacturing scale-up, but profitability remains years away.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
